ZSP1241 / Guangdong Zhongsheng Pharma - LARVOL DELTA

Zhongsheng Pharma’s FGFR4 inhibitor awarded patent in US (GBI Health) - "China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (002317.SZ) announced receiving a patent certification relating to its fibroblast growth factor receptor 4 (FGFR4) inhibitor from the United States Patent and Trademark Office. ZSP1241 has shown anti-tumor activities in liver and gastric cancer human cell xenotransplantation (CDX) lines, or human tumor tissue derived xenograft (PDX) models."

Patent • Gastric Cancer • Gastrointestinal Cancer • Oncology

Zhongsheng Pharma’s FGFR4 inhibitor patented in Korea (GBI Health) - "China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (002317.SZ) announced receiving patent protection from the Korean Intellectual Property Office for its ZSP1241, a home-grown fibroblast growth factor receptor 4 (FGFR4) inhibitor."

Patent • Oncology

A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=90; Recruiting; Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd.; Trial completion date: Nov 2020 ➔ Oct 2021; Trial primary completion date: Oct 2020 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor